Results 11 to 20 of about 5,863 (219)

Immunology and efficacy of MF59-adjuvanted vaccines [PDF]

Human Vaccines & Immunotherapeutics, 2018
Adjuvants are included in vaccine formulations to enhance the immunogenicity and efficacy of vaccines. MF59® is an oil-in-water emulsion adjuvant and licensed for use in pandemic and seasonal influenza vaccines in many countries.
Eun-Ju Ko, Sang-Moo Kang
doaj   +3 more sources

AS03- and MF59-Adjuvanted Influenza Vaccines in Children [PDF]

Frontiers in Immunology, 2017
Influenza is a major cause of respiratory disease leading to hospitalization in young children. However, seasonal trivalent influenza vaccines (TIVs) have been shown to be ineffective and poorly immunogenic in this population.
Amanda L. Wilkins, Dmitri Kazmin, Giorgio Napolitani, Elizabeth A. Clutterbuck, Bali Pulendran, Bali Pulendran, Bali Pulendran, Bali Pulendran, Claire-Anne Siegrist, Andrew J. Pollard   +9 more
doaj   +4 more sources

Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children [PDF]

International Journal of Infectious Diseases, 2019
Objective: To demonstrate the potential of an MF59-adjuvanted inactivated trivalent seasonal influenza vaccine (aIIV3; Fluad™) to improve the immune response in young children, we review the immunogenicity, efficacy, and safety/tolerability of aIIV3 from
Sanjay S. Patel, Svetlana Bizjajeva, Kelly Lindert, Esther Heijnen, Janine Oberye   +4 more
doaj   +3 more sources

Rational Development of a Novel Emulgel Adjuvant for Single-Shot Effective Vaccination: A Multivariate Analysis Approach. [PDF]

Adv Mater
Using multivariate analysis, a novel emulgel adjuvant is developed by combining key nanoemulsion formulation variables–hydrogel trapping, small globule size, and mannide monooleate surfactant–achieving 10× greater immunogenicity than MF59 in mice after a single shot.
Shalash AO, Hussein WM, Nahar UJ, Wang J, Lu L, Azuar A, Kiong JJE, Koirala P, Khalil ZG, Toth I.   +9 more
europepmc   +2 more sources

Relapse of polymyalgia rheumatica following adjuvanted influenza vaccine: A case-based review [PDF]

, 2020
Polymyalgia rheumatica (PMR) is the most common inflammatory rheumatological condition affecting individuals aged >50 years. There have been rare reports of PMR and other vasculitides developing within 3 months of influenza vaccination.
Bassendine, Margaret F., Bridge, Simon
core   +1 more source

The antibody landscapes following AS03 and MF59 adjuvanted H5N1 vaccination

npj Vaccines, 2022
Abstract Current seasonal and pre-pandemic influenza vaccines induce short-lived predominantly strain-specific and limited heterosubtypic responses. To better understand how vaccine adjuvants AS03 and MF59 may provide improved antibody responses to vaccination, we interrogated serum from subjects who received 2 doses of inactivated ...
Johannes B. Goll, Aarti Jain, Travis L. Jensen, Rafael Assis, Rie Nakajima, Algis Jasinskas, Lynda Coughlan, Sami R. Cherikh, Casey E. Gelber, S. Khan, D. Huw Davies, Philip Meade, Daniel Stadlbauer, Shirin Strohmeier, Florian Krammer, Wilbur H. Chen, Philip L. Felgner   +16 more
openaire   +5 more sources

Nanoparticle-Based Bivalent Swine Influenza Virus Vaccine Induces Enhanced Immunity and Effective Protection against Drifted H1N1 and H3N2 Viruses in Mice

Viruses, 2022
Swine influenza virus (SIV) circulates worldwide, posing substantial economic loss and disease burden to humans and animals. Vaccination remains the most effective way to prevent SIV infection and transmission.
Pan Tang, En-hui Cui, Wen-chi Chang, Chen Yu, Hao Wang, En-qi Du, Jing-yu Wang   +6 more
doaj   +1 more source

Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells. [PDF]

PLoS ONE, 2017
MF59 is an oil-in-water emulsion adjuvant approved for human influenza vaccination in European Union. The mode of action of MF59 is not fully elucidated yet, but results from several years of investigation indicate that MF59 establishes an ...
Rossella Cioncada, Marcella Maddaluno, Hoa Thi My Vo, Matthew Woodruff, Simona Tavarini, Chiara Sammicheli, Marco Tortoli, Alfredo Pezzicoli, Ennio De Gregorio, Michael C Carroll, Ugo D'Oro, Diego Piccioli   +11 more
doaj   +1 more source

Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity

Vaccines, 2021
Influenza poses a huge threat to global public health. Influenza vaccines are the most effective and cost-effective means to control influenza. Current influenza vaccines mainly induce neutralizing antibodies against highly variable globular head of ...
Zhuofan Li, Yiwen Zhao, Yibo Li, Xinyuan Chen   +3 more
doaj   +1 more source

Comparative Study on the Efficacy of MF 59, ISA70 VG, and Nano-Aluminum Hydroxide Adjuvants, Alone and with Nano-Selenium on Humoral Immunity Induced by a Bivalent Newcastle+Avian Influenza Vaccine in Chickens [PDF]

Archives of Razi Institute, 2021
Newcastle disease (ND) and Avian influenza (AI) are the major problems and the most economically important viral diseases in the poultry industry; therefore, vaccination against these diseases is considered one of the most effective ways of prevention ...
M Radmehri, A Talebi, A Ameghi Roudsari, S. M Mousaviyan, M. A. J Gholipour, M Taghizadeh   +5 more
doaj   +1 more source